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Pyrrolizidine alkaloids in herbal teas and teas 
 
BfR Opinion No. 018/2013 of 5 July 2013 
 
Pyrrolizidine alkaloids are secondary metabolites produced by a large number of plant spe-
cies all over the world as protection against herbivores. The occurrence of pyrrolizidine alka-
loids in plants varies widely, depending on the plant species and the part of the plant, and is 
also influenced by other factors (e.g. climate, soil properties). Due to their potentially harmful 
effects, 1,2-unsaturated pyrrolizidine alkaloids (PAs) in particular are undesirable in food and 
feed, as they can lead to acute liver damage when consumed in high doses. In animal stud-
ies, some PAs have proven to be genotoxic carcinogens.  
 
The BfR is currently conducting a research project on the "Determination of Pyrrolizidine Al-
kaloids in Food and Feed". In the project 221 different commercially available herbal tea and 
tea samples as well as herbal drugs were analyzed for their PA content. Based on the analy-
ses of the following herbal tea varieties the resulting exposure was estimated: baby fennel 
tea, fennel tea, chamomile tea, herbal tea, peppermint tea, nettle tea and melissa tea. The 
selection of tea varieties is not representative. The first data collected during the research 
project are to be verified, e.g. within the food monitoring programme. 
According to the first results total PA contents ranging from 0 to 3.4 milligrams per kilogram 
of dry product in the tested herbal tea and tea samples have been determined. For the as-
sessment of possible health risks the BfR used the MOE (Margin of Exposure) approach, 
which is internationally used to estimate the potential risk of substances with genotoxic and 
carcinogenic effects. The MOE is calculated from human exposure as a measure of the ex-
tent of contact with a substance relative to the effective dose established or calculated in 
animal tests for a given tumour incidence. It is assumed here that an MOE of 10000 or higher 
for genotoxic carcinogens poses little health risk. 
Although unexpectedly high PA contents were measured in individual samples, it is improb-
able that short-term intake (up to 14 days) poses a health risk for adults and children. In view 
of considerable PA contents, conclusions regarding health impairment due to the regular 
consumption of highly contaminated tea infusions are subject to large uncertainties, as there 
are considerable variations in PA contents, also for the same tea variety. For consumers 
(adults and children) with an average consumption of amounts of herbal tea and tea who do 
not favour a specific variety, health impairment due to chronic intake of PAs is improbable, as 
the MOE values are above 10000. Based on the first results of the project the MOE value for 
the intake of PAs is considerably below 10000 for people who frequently drink large quanti-
ties of herbal tea and tea. Therefore, for longer-term consumption of products with high PA 
contents, there is a risk of health impairment, particularly in the case of children, pregnant 
women and breast feeding mothers. 
The potential risk for the consumer can be reduced by following the general recommendation 
for variety and diversity in the choice of foods. This can prevent one-sided exposure to vari-
ous potentially health-threatening substances that are expected to sporadically occur in low 
amounts in food. In particular parents are advised not to offer their children herbal teas and 
tea, exclusively. Pregnant and breastfeeding women should vary their consumption of herbal 
teas and tea with other beverages. 
Due to the genotoxic and carcinogenic effects of PAs, the BfR is of the opinion that efforts 
should be made to minimise the PA contents in herbal teas and teas. This is also necessary 
since possible additional exposure to PAs from other food sources (e.g. honey) may occur. 
The BfR recommends analysis of PA contents in herbal tea and tea batches prior to market-
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ing and research to uncover the cause of the high PA contents in the products in question by 
the economic operators. The food control authorities should analyze PA levels in tea and 
herbal tea available on the market. 
 
 
 
 
 
 
BfR risk profile: 
Occurrence of pyrrolizidine alkaloids in herbal tea and tea varieties 
(Opinion no. 18/2013) 
A Affected group 
General population, pregnant women, breastfeeding women, 
children 
 
 
B 
Probability of health 
impairment due to the 
longer-term consumption 
of products with high 
contents 
Practically 
Ruled out Improbable Possible Probable Certain 
C 
Severity of health impair-
ment due to the longer-
term consumption of 
products with high con-
tents 
The severity of the impairment may vary. 
D Robustness of the avail-
able data 
High: 
the most important data is avail-
able and is free of contradictions 
Average: 
some important data is 
missing or is contra-
dictory 
Low:  
much important data is missing or 
is contradictory 
E Possibility of consumer 
control [1] Control not necessary 
Can be controlled by 
taking precautionary 
measures 
Can be controlled by 
refraining from con-
sumption 
Not controllable 
 
Text fields with dark blue background highlighting characterise the properties of the risk assessed in this opinion 
(for more detailed information, please refer to the text in BfR Opinion No. [No./Year] dated [Day/Month/Year). 
 
 
Explanations 
 
The risk profile is designed to visualise the risk outlined in the BfR Opinion. It is not designed to permit risk comparisons. The risk 
profile should only be read in conjunction with the opinion. 
Line E - Possibility of consumer control 
[1] –  The food producers are called upon to minimise contents of pyrrolizidine alkaloids (Consumers cannot control these contents.) Parents are 
advised not to exclusively offer their children herbal teas and tea. Pregnant and breastfeeding women should vary their consumption of herbal teas 
and tea with other beverages (precautionary measure). 
 
The details in the line "Possibility of consumer control" are not to be seen as a recommendation of the BfR but are of descriptive character. The 
BfR has outlined recommendations for action in its Opinion. 
 
FEDERAL INSTITUTE FOR RISK ASSESSMENT (BfR) 
 
 
1  Subject of the assessment 
 
The BfR is currently conducting a research project on the "Determination of Pyrrolizidine Al-
kaloids in Food and Feed". In the frame of this project 221 different commercially available 
herbal tea and tea samples1 as well as herbal drugs (184 herbal tea and tea samples from 
food retailers and 37 "medicinal teas" from pharmacies) were analysed for the content of 1,2-
unsaturated pyrrolizidine alkaloids (PAs)2. The samples were not collected by representative 
sampling of the corresponding products on the German market. 
                                               
1
 The terms "herbal tea" and "tea" correspond to the definitions in the guidelines (1) 
2
 In the following, PAs are used to designate pyrrolizidine alkaloids with 1,2-unsaturated base structure 
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Those PA which are commercially available as standard substances were determined by the 
used analytical method. The determined compounds are intermedine, lycopsamine, 
heliotrine, heliotrine-N-oxide, echimidine, lasiocarpine, lasiocarpine-N-oxide, monocrotaline, 
monocrotaline-N-oxide, retrorsine, retrorsine-N-oxide, trichodesmine, seneciphylline, seneci-
phylline-N-oxide, senecionine, senecionine-N-oxide and senkirkine. For each sample, the 
total PA content was calculated as the sum of measured individual contents. 
 
The following herbal tea varieties were included in the estimation of exposure: baby fennel 
tea, fennel tea, chamomile tea, herbal tea, peppermint tea, nettle tea and melissa tea. Other 
tea varieties (e.g. green tea, rooibos tea, black tea) were not included in the exposure esti-
mation due to the small number of samples. 
 
2   Findings 
 
Based on the first results of non-representative surveys within the framework of the BfR re-
search project, total PA contents from 0 to 3430 µg/kg dry matter were measured in the 
herbal tea and tea samples. Although unexpectedly high PA contents were measured in indi-
vidual herbal tea and tea samples, it is seen as improbable that this poses an acute health 
risk, even in high doses. 
 
In view of the genotoxic and carcinogenic effects of PAs, efforts should be made to minimise 
the PA contents in herbal teas and teas and thus minimizing the potentially higher cancer risk 
of frequent consumers and in particular of children, whose higher sensitivity to PA-related 
effects should be taken into account. This is also necessary since possible additional expo-
sure to PAs from other food sources may occur (e.g. honey). 
 
In the assessment of long-term intake, the BfR continues to use the MOE approach (Margin 
of Exposure)3, which is the international standard for estimating the potential risk of sub-
stances with genotoxic and carcinogenic effects. Based on animal studies, it is assumed that 
an MOE value of 10000 or higher for genotoxic carcinogens poses little health risk. Accord-
ing to the results of the BfR research project, the MOE value for PA intake by adults and 
children would be considerably below 10000 for frequent consumers of certain herbal tea 
and tea infusions. 
 
Based on the available data, the BfR concludes that those adults and children who belong to 
the frequent consumers of herbal tea infusions are possibly at increased cancer risk, particu-
larly if they consume products with high PA contamination over longer periods of time. 
 
The BfR once again recommends that the total exposure of consumers to genotoxic and car-
cinogenic PAs from various food sources should be kept as low as possible.  
 
In order to avoid the marketing of contaminated batches and to protect the consumer, it is 
recommended that herbal tea batches that are to be brought onto the market be checked for 
PA content beforehand. 
Research activities to uncover the cause of the high PA content in the products in question 
by economic operators is regarded as essential. These include botanical analysis of the plant 
                                               
3
 The MOE approach (Margin of Exposure) is a method used to describe the risk occurring due to exposure to 
carcinogenic and/or genotoxic substances in food. The MOE value is the ratio of the following two factors for a 
specific population: the smallest dose with which a minor but measurable negative effect is observed and the level 
of exposure to the substance in question. The higher the MOE value, the lower the potential health risk to the 
consumer (2). 
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material to which the occurrence of the PAs found in the herbal tea and tea samples is attrib-
uted as well as a review of "good agricultural harvesting practice". 
 
In general, the possibility of reducing PA contents through improved cultivation, harvesting 
and cleaning methods should be reviewed. 
 
The BfR also recommends that the food control authorities should perform checks to deter-
mine the PA contents of herbal tea and tea samples. Furthermore, the gathering of represen-
tative data on PAs in herbal tea and tea samples as part of the food monitoring process is 
recommended. 
 
3   Statement of reasons 
 
3.1     Risk assessment 
 
3.1.1  Agent 
 
Pyrrolizidine alkaloids are secondary plant compounds and are undesirable substances in 
food and feed (3-5). Over 500 different pyrrolizidine alkaloids and their N-oxides are known 
(6), and their occurrence is expected in more than 6000 plant species based on chemotax-
onomic considerations (7). Plants containing pyrrolizidine alkaloids primarily belong to the 
Asteraceae, Boraginaceae and Fabaceae (Leguminosae) (8). 
 
Pyrrolizidine alkaloids are taken to mean esters from a 1-hydroxymethylpyrrolizidine (necine 
base) and aliphatic monocarbon or dicarbon acids (necine acids). Depending on the esterifi-
cation of one or both hydroxyl groups, pyrrolizidine alkaloids can occur as monoesters or 
diesters. Esterification with two carboxyl groups of a dicarbon acid results in a cyclical 
diester. Depending on the structure of the necine base, a distinction is primarily made be-
tween pyrrolizidine alkaloids of the retronecine, heliotridine, otonecine or platynecine type 
(Figure 1). Pyrrolizidine alkaloids of the retronecine and heliotridine type are diastereomers 
at position C-7 (9). 
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Figure 1: Structural formula of important necine bases 
 
3.1.2    Risk potential 
 
The current knowledge on toxicology, which is summarized in the following, forms the basis 
for the health assessment of pyrrolizidine alkaloids in food including herbal tea and also 
formed the basis for previous BfR opinions on this topic (10, 11).  
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3.1.2.1  Structural chemical basics 
 
The following structural features are characteristic for the typical toxic effects of pyrrolizidine 
alkalloids which are transmitted to the liver and partly also the lung (3, 4, 12-14):  
 Double bonding in the 1,2-position of the pyrrolizidine ring,  
 Esterification of the hydroxymethyl group at C-1 of the ring system or - if 
      present - the hydroxyl group at C-7,  
 
 Branching of the alkyl side chain in at least one of the esterified carboxylic acids. 
 
Pyrrolizidine alkaloids with 1,2-unsaturated necine structure esterified with at least one 
branched C5-carboxylic acid are associated with hepatotoxic, carcinogenic and mutagenic 
effects (13, 15). This includes the unsaturated pyrrolizidine alkaloids of the retronecine, 
heliotridine and otonecine type but not the saturated pyrrolizidine alkaloids of the platynecine 
type (Figure 1).  
 
It is generally considered that the effects of esters of the hydroxymethyl group at C-1 (mono-
ester) are enhanced if a second OH group is present in position C-7 of the necine. The effect 
is believed to be further strengthened if this OH group is also esterified (diester). The strong-
est toxic and carcinogenic effects are attributed to cyclic diesters (12, 13, 16).  
With the exception of pyrrolizidine alkaloids of the otonecine type, the plants in question gen-
erally contain combinations of the free unsaturated pyrrolizidine alkaloids with their N-oxides 
(6). The oral toxicity of the latter substances is regarded as to be comparable to that of the 
reduced form of the alkaloids, to which they are metabolised in the colon by reductases. 
 
3.1.2.2  Toxicokinetics and mode of action 
 
In animal experiments, PAs are generally rapidly absorbed following peroral intake. Following 
partial metabolism, excretion occurs primarily via the kidney and to a lesser extent in the fae-
ces (14). The PAs remaining in the organism mainly take the form of metabolites bound to 
tissue components (3).  
 
No quantitative data is available on the oral bioavailability of PAs in humans. In vitro data 
suggests that both activation and detoxification take place. 
 
The PAs are metabolised to pyrrole derivatives through hydrolysis, N-oxidation and dehydro-
genation of the pyrrolizidine ring. The necine acids released during hydrolysis do not appear 
to be of toxicological relevance. Any N-oxide metabolites that are formed are highly soluble 
in water and are excreted extremely quickly in the urine, and this metabolic pathway is there-
fore seen as a detoxification pathway. The transformation of the uncleaved esters to toxic 
pyrrolic esters in the liver due to mixed-function oxidases, however, constitutes a toxification 
reaction. Pyrroles of this type are highly reactive alkylating agents that can react with nucleo-
philic groups of nucleic acids and proteins to form adducts and are considered active me-
tabolites that are the cause of the hepatotoxic, hepatocarcinogenic and mutagenic effects of 
PAs (4, 14, 16-21).  
The mechanism behind the carcinogenic effect (direct or indirect DNA effects) is not yet 
known. The fact that PAs also cause extrahepatic lesions is attributed to the hydrolysis of the 
pyrrolic esters, which forms carcinogenic and developmental-toxic pyrrolic alcohols like 
(±)6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP) (3, 14). The latter are less 
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short-lived and more readily water-soluble than the pyrrolic esters, which means that they are 
more easily distributed in the human body (3, 14). 
 
Species differences with regard to sensitivity to PA-induced toxicity are attributed to differ-
ences in the balance between detoxifying and toxic metabolism paths (20). In vitro studies in 
which the metabolism of riddelliine to DHP and riddelliine-N-oxide occurred in the presence 
of human liver microsomes to a similar extent as with rat liver microsomes (19) are, like simi-
lar findings with retrorsine, retrorsine-N-oxide, riddelliine-N-oxide and monocrotaline-N-oxide 
(18), seen as an indication that findings from rat experiments on tumour induction by PAs are 
relevant to humans. 
 
Unsaturated PAs and its pyrrole derivatives cross the placenta and pass to breast milk. Rat 
foetuses and nursed male rats whose mother animals were feed with unsaturated Pas, ex-
hibited e.g. acute and chronic liver damage (3). 
 
3.1.2.3 Toxicity in humans and animals 
 
Various data on the toxicology of unsaturated PAs hve been published based on health im-
pairments to humans and livestock observed around the world due to the intake of plant spe-
cies containing unsaturated PAs (country-specific intake as food or medication, contamina-
tion of food or feed) as well as relevant feeding studies. For information on this, we refer pri-
marily to the corresponding monographs and review studies(3, 4, 14, 16, 22-24). Liver dis-
eases with fatalities, some of them epidemic, have been observed in Pakistan, India and 
Afghanistan, which only recently saw another regional outbreak (25) following the consump-
tion of grain contaminated with the seeds of Heliotrope (Heliotropium spp.) or Crotalaria va-
rieties, and there have been cases of endemic poisoning in Jamaica from so-called "bush 
teas" containing parts of Crotalaria and Common groundsel (Senecio). Examples from live-
stock management include the frequent occurrence of liver cirrhosis in slaughtering cattle 
who have eaten Alpine ragwort (Senecio alpinus) with hay and silage as well as the senecio-
ses associated with liver degeneration described in horses after the intake of Senecio varie-
ties during grazing (3, 16, 26-31). 
 
The toxic effects of unsaturated PAs consumed in large doses over a short period of time are 
manifest in humans chiefly in liver in the form of veno-occlusive changes (veno-occlusive 
disease, VOD), and the occlusion of the central subobular liver veins is pathognomonic. The 
toxicity signs are frequently not observed until several days after exposure, which means it is 
often difficult to identify the cause of poisoning. The initial clinical signs of acute and sub-
acute intoxication are increasing pain in the upper abdomen, the rapid development of as-
cites within the space of a few days and sometimes oliguria and oedemas at the feet. Ac-
companying symptoms may be nausea and vomiting, and more seldom jaundice and fever. 
Enlargement and hardening of the liver is generally observed after a few weeks, often in 
combination with massive pleural effusion. In addition to VOD, some PAs (e.g. monocro-
taline) also induce pulmonary arterial hypertension, which can result in acute right-heart fail-
ure (Cor pulmonale) (3, 4, 26). 
 
The acute form of the disease has a high mortality rate, with death occurring anywhere be-
tween 2 weeks and over 2 years following exposure. Full recovery from hepatic VOD is pos-
sible. A chronic disease can develop among survivors of an acute hepatic VOD or with long-
term intake of small quantities of unsaturated PAs and result in liver cirrhosis. This is non-
specific, thus a causal diagnosis is also difficult in these cases. Children appear to be more 
sensitive than adults (see 3.1.2.3.1) (4, 32-34). Similar findings were documented in experi-
ments on rats (14). In pathological terms, acute intoxication with unsaturated PAs is charac-
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terised by lobule-central toxic liver cell necrosis (3, 4, 16). Values for the LD 50 of PAs follow-
ing intraperitoneal (i.p.) administration can be found in Mattocks (4). Studies have been con-
ducted with retrorsine-N-oxide after peroral administration in which an LD 50 of 48 mg/kg 
body weight (bw) (administration over the course of seven days) was observed in rats (4). 
 
Enlarged hepatocytes with big hyperchromatic cell nuclei are typical for the chronic liver tox-
icity of unsaturated PAs in animals. This is seen as a morphological manifestation of the an-
timitotic effect of unsaturated PAs and is not found in humans (3). In a chronic rat study in 
which riddelliine was administered by gavage (treatment on 5 days per week for 105 weeks), 
a no-observed-adverse-effect-level (NOAEL) of 0.01 mg/kg bw/day (hepatocytomegaly at 
0.033 mg/kg bw/day) was found for non-neoplastic changes (24). 
 
Animal experiments give clear evidence of the carcinogenic effect of certain unsaturated PAs 
(lasiocarpine, monocrotaline, riddelliine) and a corresponding risk is considered to exist for 
humans (3, 16, 22-24, 35, 36). In the case of other unsaturated PAs, the animal experiments 
using the compound itself or its active metabolites also indicate a carcinogenic effect (e.g. 
isatidine, jacobine, retrorsine, seneciphylline, senkirkine, petasitenine), but the data are in-
complete (3, 22, 36, 37). In many cases, compounds that showed themselves to be carcino-
genic in animal experiments also had positive results for mutagenicity testing (3, 38). The 
lowest BMDL10 (benchmark dose lower confidence limit 10%) of 0.073 mg/kg bw/day was 
derived from a carcinogenicity study using lasiocarpine based on findings in male rats (35, 
39). In this study, doses of 7, 15, and 30 mg lasiocarpine/kg (equivalent to 0.35, 0.75 and 1.5 
mg/kg bw/day) was administered orally to Fischer 344 rates over 104 weeks. Liver angiosar-
comas were observed in 13 out of 23 male and 2 out of 23 female rats in the highest dose, 
11 out of 23 male and 7 our of 24 female rats in the medium dose and 5 out of 24 male and 8 
out of 22 female rats in the lowest dose (35). 
 
The embryotoxic effect of certain PAs is known from animal experiments, but the data is 
scarce and there are no insights into possible developmentally related toxic effects in hu-
mans (3, 4). 
 
3.1.2.3.1 Poisoning in humans 
 
Based on the description of poisoning cases following the intentional or accidental intake of 
plants containing PAs, information is scarce allowing only limited conclusions with regard to 
the doses of unsaturated pyrrolizidine alkaloids that can lead to toxicity in humans following 
short or long-term exposure (3, 5). 
 
Acutely toxic doses 
 
Only two cases are described in the literature that contain robust details about the dose re-
garding poisoning following short-term exposure(4 to 14-day). The cases in question are the 
disease of a 6 month-old girl (body weight: 6 kg) and a 2 month-old boy (body weight: un-
known), both of Mexican-American origin, who were given Senecio longilobus as a herbal tea 
(40-42). The girl initially exhibited ascites and pleural effusion, followed by sinusoidal liver 
fibrosis after 2 months and liver cirrhosis 6 months later. The boy suffered from haemateme-
sis, developed jaundice with pronounced hepatomegaly, exhibited central nervous cramps, 
bradycardia and apnoea periods and died after 6 days. 
 
Referring to their dry weight, the herbal teas contained 0.3% PAs (mainly riddelliine) and 1% 
N-oxides (mainly of retrorsine, in lesser amounts from seneciphylline and senecionine) in the 
first case and 0.5% PAs and 1% N-oxides in the second. Based on the findings of analysis of 
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the herbal tea infusions and the administration schedule, it was calculated that the girl weigh-
ing 6 kg ingested a total of between 70 and 147 mg, equivalent to 12 - 25 mg/kg bw over a 2-
week period, while the boy (assumed body weight: 5.5 kg) (3) ingested a total of approx. 66 
mg, equivalent to 17 mg/kg bw of PAs over a period of 4 days. This supplies an estimated 
daily dose of 0.8 - 1.7 mg/kg bw for the girl and 3 mg/kg bw for the boy for a mixture of PAs 
with riddelliine and retrorsine-N-oxide as the main components. 
 
Toxic doses with medium and longer-term exposure 
 
The literature describes a case of VOD following four-month consumption of a preparation of 
comfrey leaves (no details of the Symphytum species) containing up to 0.27 g of alka-
loids/kg. In addition, a herbal tea containing PAs had been consumed over a lengthy period 
of time. The authors estimated that a dose of 15 µg alkaloids/kg bw/day was consumed over 
a period of six months (main alkaloid: echimidine) (3, 39, 43). This assumption is subject to 
uncertainty, however, as the person in question consumed PAs from different sources (3, 
39). 
 
VOD - ending fatally in one case - was also diagnosed in four Chinese women following con-
sumption of a herbal tea based on Heliotropium lasiocarpum over a period of 19 to 46 days. 
It is estimated that the women ingested a daily dose of 0.59, 0.49 (fatal course), 0.60 or 0.71 
mg of PAs (heliotrine)/kg bw/day over a period of 45, 46, 19 or 21 days (3, 44-46). 
In two Indian cases of VOD following 20 to 50-day consumption of Heliotropium eichwaldii for 
medicinal purposes, exposure was calculated as 3.3 mg of PAs (heliotrine)/kg bw/day (3, 
47). 
 
In frequent cases of VOD in Afghanistan and India due to the consumption of grain contami-
nated with seeds containing PAs, it was estimated that a daily dose of 0.033 or 0.66 mg of 
PAs/kg bw/day were ingested over periods of six or two months, and the main alkaloids were 
assumed to be heliotrine or crotananine and crotaburmine (3, 48-50). 
 
3.1.2.3.2 Existing assessments of the BfR and other national and international 
bodies 
 
The WHO determined back in 1988 that the toxic effects of PAs are cumulative. This is why 
low chronic exposure can also pose a health risk(3). The predominant long-term effects in 
humans are liver cirrhosis and the development of tumours. To date, however, there have 
been no robust follow-up or epidemiological studies investigating a dose-effect relationship 
over longer periods of time. With regard to the aforementioned case of liver disease after PA 
consumption through comfrey leaves (43), in which the daily intake was in the order of 15 µg 
PA (main alkaloid: echimidine)/kg bw, this dose was converted into a heliotrine equivalent. 
As PAs from Symphytum officinale have a weaker effect, the ratio of LD 50 values (i.p. appli-
cation) was used to calculate a dose equivalent of 10 µg heliotrine/kg bw and day, of which it 
was assumed that it would still lead to diseases in humans. 
 
In 1992, maximum levels not to be exceeded were stipulated for pyrrolizidine alkaloids with a 
1,2-unsaturated necine structure and their N-oxides in medications in Germany (“Stufenplan-
verfahren”), and these maximum levels are still in force. In the case of medications with rec-
ognised applications in line with monographs pursuant to section 25 para. 7 of the German 
Medicinal Products Act (AMG), it is stipulated that the daily exposure with maximum dose 
may not exceed the following levels: 100 µg PA/person for external use, 1 µg PA/person for 
internal use, 10 µg PA/person with the use of coltsfoot leaves as a tea infusion. Moreover, 
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the recommended duration of use is to be limited to a maximum 6 weeks a year for these 
medications, and they should not be used for non-topical application during pregnancy and 
nursing. The exceptions to this stipulation - alongside certain homeopathic medications - are 
medications containing PAs where the maximum dose does not result in daily exposure ex-
ceeding 0.1 µg PA/person for internal application and 10 µg PA/person for external applica-
tion (15). 
 
In 2001, the "Australia New Zealand Food Authority" (ANZFA) primarily looked at the "non 
cancer effects" and proposed a "tentative NOAEL" for all PAs of 10 µg/kg body weight 
(bw)/day on the basis of the data from the aforementioned case description. Using an uncer-
tainty factor of 10, this would supply a PTDI (provisional tolerable daily intake) of 1 µg/kg 
bw/day. In addition, it was emphasised that there was no evidence for the carcinogenicity of 
PAs in humans (51).  
 
In 2002, the Senate Commission on Food Safety (SKLM) of the Deutsche Forschungsge-
meinschaft (DFG, German Research Foundation) came to the conclusion that the available 
data on PA contents in honey obtained from plants containing PAs (e.g. Echium spp. honey 
or Senecio spp. honey) and on consumer exposure to PAs is to be considered insufficient. 
The data basis on the toxicology of these kinds of PAs and on their metabolism in humans 
was also seen as being incomplete, with the result that it was not possible to publish a con-
clusive risk assessment. The SKLM also recommended that special attention be primarily 
paid to products made using pollen from plants containing PAs. It said that these products 
were brought onto the market as food supplements and probably consumed in large quanti-
ties (52). 
 
In 2005, the "Dutch National Institute for Public Health and the Environment" (RIVM) as-
sessed "non-cancer effects" and also included data from experiments on animals. Based on 
the NOAEL of 0.01 mg/kg bw and day for non-neoplastic changes from the chronic rat study 
using riddelliine (24) and an uncertainty factor of 100, a "tolerable daily intake" (TDI) of 0.1 
µg/kg bw/day was calculated. With regard to the risk assessment of a carcinogenic effect of 
the PAs, the RIVM calculated a so-called "virtually safe dose" (VSD) for PAs of 
0.00043 µg/kg bw and day based on the same study. This is the dose that is expected to still 
result in a cancer risk of one to one million (53). 
 
In 2008, the "Committee on Toxicity of Chemicals in Food, Consumer Products and Envi-
ronment" (COT) in the UK also assessed "non-cancer effects". From the rat study with riddel-
liine, applying an uncertainty factor of 100 and a NOAEL of 0.01 mg/kg bw/day, it was con-
cluded that "non-cancer effects are not to be expected below a dose of 0.1 µg riddelliine/kg 
bw/ day. The COT recommended that the ratio of LD 50 values could be used to convert 
other PAs into riddelliine equivalents. With regard to their carcinogenic effect, the COT re-
garded PAs as a group of substances with cumulative effect. The lowest BMDL10 of 0.073 
mg/kg bw/day derived from the study of lasiocarpine and male rats (35) was used to estimate 
the MOE (Margin of Exposure) for individual PAs or their sum. A MOE of 10000 was as-
sumed in line with the EFSA (European Food Safety Authority) guidelines (2). On this basis, 
COT concluded that "MOEs of 10000 and above, corresponding to doses of up to 0.007 µg 
/kg b.w./day, would be unlikely to be of concern." (39). 
 
A "Discussion paper on pyrrolizidine alkaloids" of the Codex Committee on Contaminants in 
Food published in 2011 summarises the available assessments, regulations and analytical 
methods as well as data on the occurrence and toxicity of pyrrolizidine alkaloids and provides 
recommendations for a future assessment by JECFA (Joint FAO/WHO Expert Committee on 
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Food Additives) as well as for the establishment of a code of practice for the avoidance and 
reduction of contamination with PAs (5). 
 
Up to 2011, the BfR based its risk assessment of PAs in food on the assessment approach 
agreed with the medicinal product sector, an approach that was established in 1992 in con-
nection with the aforementioned “Stufenplanverfahren” for medications containing PAs. As 
was the case with certain medications, the BfR also called for PA levels in foods to remain 
below a maximum daily intake of 0.1 µg PA/person wherever possible (15). In its opinion 
dated 11 August 2011 (10) the BfR referred to the outcome of an expert meeting on 4 March 
and recommended that the total exposure of consumers to genotoxic and carcinogenic 1,2-
unsaturated pyrrolizidine alkaloids (PAs) in various foods be kept as low as possible. Based 
on the MOE approach, which is standard in the EU, and in line with the COT assessment, 
the BfR also recommended that consumers should as possible not exceed a daily intake of 
0.007 µg of unsaturated PA/kg body weight (bw). This corresponds to compliance with an 
MOE of at least 10000. This assessment is still valid and is explained in the "Risk characteri-
sation" section (see 3.1.4). Following an evaluation of analysis data on the occurrence of 
PAs in honey, the BfR said efforts were necessary to reduce PA contents in honey in order to 
minimise the potential risks to frequent consumers of honey and in particular children. 
 
In the opinion on the assessment of pyrrolizidine alkaloids as undesired substances in feed 
in 2007, the Panel on Contaminants in the Food Chain of the European Food Safety Author-
ity (CONTAM Panel) outlined gaps in knowledge with regard to exposure and pointed out 
that the occurrence of PAs in honey merits particular attention. It also recommended that 
analytical investigation of occurrence in feed be focused on selected PAs: senecionine, se-
neciphylline, erucifoline, monocrotaline, trichodesmine, heliotrine, indicine, intermedine and 
lycopsamine (54). In 2011, the CONTAM Panel of EFSA published a new expert opinion on 
the risk assessment of pyrrolizidine alkaloids in food and feed (55). This expert opinion also 
chose the MOE approach to estimate the potential cancer risk of PA exposure in food, also 
using the BMDL10 of 0.073 mg/kg bw/day from the study with lasiocarpine and male rats 
(35) as a point of reference. Although it also considered other potential sources of PAs, the 
CONTAM Panel was unable to quantify exposure from further foodstuffs other than honey 
due to lack of data. In the case of infants and children, who consume large amounts of 
honey, the panel, like the BfR, concluded that the MOE value could be considerably below 
10000, which would indicate possible health risks. 
 
3.1.3 Analysis 
 
3.1.3.1 Analytical concept 
An analytical method for the determination of PAs in herbal tea and tea samples was devel-
oped and validated in-house at the Federal Institute for Risk Assessment (BfR) as part of a 
research project. This method was used to analyse herbal tea and tea samples from German 
retailers for 17 PAs. The total PA content of each sample was calculated as the sum of the 
measured individual contents and was used to assess the health risk due to the occurrence 
of PAs in herbal tea/tea varieties. 
 
3.1.3.2 Analytical method 
 
Detection of PAs is based on acidic extraction, clean-up and enrichment by means of solid 
phase extraction followed by liquid chromatographic separation and mass spectrometric de-
tection (LC-MS/MS). Using this method those 17 PAs are determined, which are currently 
commercially available as standard substances (echimidine, heliotrine, heliotrine-N-oxide, 
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intermedine, lasiocarpine, lasiocarpine-N-oxide, lycopsamine, monocrotaline, monocrotaline-
N-oxide, retrorsine, retrorsine-N-oxide, senecionine, senecionine-N-oxide, seneciphylline, 
seneciphylline-N-oxide, senkirkine and trichodesmine). Identification of these PAs in the 
samples is accomplished by comparing of retention times with those of the standard sub-
stances as well as detection of at least two transitions of the molecular ion in question to 
substance-specific fragment ions. 
 
In Table 1a the calculated limits of detection (LOD) and limits of quantification (LOQ) of the 
method for the 17 analytes are listed. 
 
Table 1a: Limits of detection (LOD) and limits of quantification (LOQ) based on DIN ISO 32645 
(56) in herbal tea and tea (results of in-house validation) 
 
Analyte LOD (µg PA/kg tea) LOQ (µg PA/kg tea) 
Echimidine 0.9 2.9 
Heliotrine 0.9 2.9 
Heliotrine-N-oxide 5.3 13.3 
Intermedine 1.5 4.7 
Lasiocarpine 1.1 3.4 
Lasiocarpine-N-oxide 5.4 12.2 
Lycopsamine 1.2 3.9 
Monocrotaline 1.0 3.2 
Monocrotaline-N-oxide 2.0 6.2 
Retrorsine 49.1 151.8 
Retrorsine-N-oxide 16.5 48.7 
Senecionine 22.1 64.1 
Senecionine-N-oxide 15.8 46.8 
Seneciphylline 2.4 7.8 
Seneciphylline-N-oxide 5.6 14.3 
Senkirkine 1.7 5.3 
Trichodesmine 1.1 3.5 
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Table 1b shows the number of samples (in absolute numbers and in percent) of each herbal 
tea variety in which at least one of the 17 tested PAs was determined above the limit of de-
tection (LOD). In the case of herbal tea 88% of samples contained at least one PA in concen-
trations above the LOD. In the case of fennel tea in 57% of samples at least one PA is de-
termined in concentrations above the LOD. 
 
Table 1b: Percentage of samples per tea variety exceeding the limit of detection in %  
Tea variety n %> LOD 
Herbal tea 42 88.1 % 
Peppermint tea 29 86.2 % 
Chamomile tea 31 87.1 % 
Fennel tea 30 56.7 % 
Baby fennel tea 9 100.0 % 
Nettle tea 12 91.7 % 
Melissa tea 8 100.0 % 
 
3.1.3.2 Evaluation of measured PA contents 
 
3.1.3.2.1 Qualitative confirmation 
 
The specificity of LC-MS/MS methods is considered very high. The identification of the 17 
individual PA substances in the samples was based on the retention times and the determi-
nation of two substance-specific mass fragments in compliance with the performance criteria 
for mass-spectrometric analytical methods according to Decision (EC) 2002/657/EC (57). 
With the method used here, a PA is consired to be identified with certainty if the retention 
time and the molecular mass correspond to the respective PA standard and at least the two 
fragment ions are formed from the molecular ion in the sample in a ratio that is comparable 
to that in the respective PA standard. Additional confirmation of the identity of the PAs was 
achieved by the standard addition approach. Selected samples containing PAs were spiked 
with defined quantities of PA standards and the increase in the mass-spectrometric signal of 
the PA in question was verified. In addition, product-ion spectra of the relevant analytes were 
recorded in selected samples. This means that the entire fragmentation pattern of the PA 
molecular ions was documented and compared with the patterns of the standard substances. 
 
3.1.3.2.2 Quantitative evaluation 
 
Selected samples with particularly high PA contents were diluted in several steps and the 
resulting reduction in the PA signal was checked for linearity. It was therefore possible to 
exclude signal enhancements or suppressions due to a matrix-based enhancement or sup-
pression of the ionisation rate and the resulting overestimation or underestimation of PA con-
tents for the PAs that were present as standard substances (58). 
 
3.1.3.3 International method validation study 
 
The developed and in-house validated method for the determination of PAs in herbal tea/tea 
is current being validated by the BfR in an international collaborative trial based on the 
ISO/IUPAC/AOAC protocol (59). The aim is to standardise the method. A further subject of 
the method validation study is a method to determine PAs in honey. 
The familiarisation round for the validation of the methods is currently in progress with 24 
international participants. 
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3.1.4 Measured total PA contents in herbal tea and tea 
 
The evaluation of PA contents in different herbal tea and tea varieties is based on data from 
a total of 221 commercially off-the-shelf samples (184 from food retailers and 37 medicinal 
teas from pharmacies) purchased in the Berlin region between October 2012 and March 
2013. The samples were not obtained by way of representative sampling of the correspond-
ing products available on the German market. The focus was on herbal teas like fennel tea, 
chamomile tea, peppermint tea and herbal tea blends. Other teas including black, green and 
rooibos tea were also analysed. 
Table 2 shows the PA contents in the tea samples purchased from retailers. The PA sum 
was calculated for each sample from the individual contents of the 17 available PAs: inter-
medine, lycopsamine, heliotrine, heliotrine-N-oxide, echimidine, lasiocarpine, lasiocarpine-N-
oxide, monocrotaline, monocrotaline-N-oxide, retrorsine, retrorsine-N-oxide, trichodesmine, 
seneciphylline, seneciphylline-N-oxide, senecionine, senecionine-N-oxide and senkirkine. 
The contents and calculations listed below always refer to the PA sum. Due to the uncertain-
ties arising with a high number of values below the limit of detection (LOD) or limit of quantifi-
cation (LOQ), the evaluation of content data was based on the approach developed for dioxin 
analysis (60) according to lower bound (LB; values < LOD => 0 or < LOQ = LOD)4, medium 
bound (MB; values < LOD or LOQ are set to half LOD or LOQ) and upper bound (UB; values 
< LOD or LOQ are set to full LOD or LOQ).  
It becomes apparent that sometimes the contents do not only vary widely in the same tea 
varieties, indicating a major difference between the minimum and maximum values, but that 
PA contents also sometimes vary considerably depending on the tea variety. Fennel tea (in-
cluding baby fennel tea) and green tea tend to have lower contents on average 
[mean(UB) = 181 or 197 µg/kg] compared to the other tea varieties, for example. In contrast 
chamomile and melissa tea show the highest average PA levels [mean(UB) = 554 or 
763 µg/kg]. 
 
 
Table 2: PA contents in different herbal tea and tea varieties by LB1, MB², UB³ in µg/kg of dry 
product 
Tea varieties  n Min Mean Median P95 Max 
LB 9 0.9 50.8 58.1 .*) 94.5 
MB 9 68.8 116.3 122.7 .*) 157.4 Baby fennel tea 
UB 9 135.8 182.5 186.4 .*) 226.1 
LB 30 0.0 47.9 1.4 527.5 904.2 
MB 30 67.8 114.9 69.2 590.6 965.5 Fennel tea 
UB 30 133.8 181.0 136.3 652.3 1026.0 
LB 31 0.0 420.8 256.1 2556.1 3428.8 
MB 31 67.8 478.9 310.2 2597.0 3435.0 Chamomile tea 
UB 31 133.8 553.7 379.0 2661.2 3441.2 
LB 42 0.0 137.2 24.5 770.7 1469.8 
MB 42 67.8 199.0 89.8 809.8 1530.5 Herbal tea 
UB 42 133.8 270.3 160.4 888.8 1589.6 
                                               
4
 Depending on the individual sample: if the value is stated as < LOD, the value was set to = 0 and used for the 
evaluation. If the value is stated as < LOQ, the LOD was used. 
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LB 29 0.0 127.2 67.8 620.2 766.1 
MB 29 67.8 188.0 131.8 671.6 827.5 Peppermint tea 
UB 29 133.8 258.5 206.9 735.6 887.2 
LB 12 0.0 197.6 91.6 .*) 1140.9 
MB 12 67.8 263.4 158.5 .*) 1205.6 Nettle tea 
UB 12 133.8 329.0 224.2 .*) 1276.1 
LB 8 32.1 646.5 649.5 .*) 1499.1 
MB 8 95.1 692.0 688.7 .*) 1528.0 Melissa tea 
UB 8 169.3 763.2 752.1 .*) 1558.7 
Data for tea varieties that were not included in the exposure assessment 
LB 8 0.0 63.9 8.1 .*) 384.1 
MB 8 67.8 128.3 74.9 .*) 435.8 Green tea 
UB 8 133.8 196.5 141.5 .*) 486.9 
LB 7 79.8 199.8 140.4 .*) 409.6 
MB 7 139.3 250.8 198.8 .*) 448.4 Rooibos tea 
UB 7 214.9 316.0 295.6 .*) 498.6 
LB 8 1.2 170.7 33.2 .*) 1001.7 
MB 8 69.1 234.0 100.5 .*) 1054.9 Black tea 
UB 8 136.4 306.2 166.9 .*) 1155.5 
*) It was not possible to calculate a 95th percentile (P95) due to the low number of tested samples. 
1Lower bound (values < limit of detection are set to 0; values < limit of quantification are set to limit of quantifica-
tion); ²Medium bound (values < limit of detection/limit of quantification are set to half the limit of detection/limit of 
quantification); ³Upper bound (values < limit of detection/limit of quantification are set to the full limit of detec-
tion/limit of quantification). 
 
3.1.5 Exposure 
 
Exposure estimates are based on the herbal teas5 listed in section 3.1.4 and Table 2 and the 
consumption data outlined in the following section 3.1.5.1. All figures on contents and con-
sumption refer to the dried herbs. Consumption figures based on the consumption of infu-
sions were converted to the dry form using the formula listed in section 3.1.5.3. 
 
Exposure estimates are calculated for adults and children. However, the consumption of 
herbal tea infusions does not refer to the different tea varieties but to all tea infusions taken 
together, as no differentiated consumption data are available. This method results in a slight 
(and desired) overestimation of exposure. This applies in particular to the tea varieties that 
tend to have lower contamination levels. The uncertainties inherent in this method have al-
ready been outlined. The results are shown for tea and herbal tea. The term "herbal tea" is 
used to describe all types of herbs declared as such that are used to make tea infusions. Tea 
(overall) means all varieties and not teas defined in more detail. 
3.1.5.1 Consumption studies 
 
NVS II National Food Consumption Study 
                                               
5
 Also see footnote 1 on the use of the terms "tea" and "herbal tea" 
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The data for consumption of tea infusions by young people and adults was take from the 
NVS II National Food Consumption Study conducted by the Max Rubner Institute (MRI). The 
NVS II is currently the most recent representative study on consumption by the German 
population. The study, during which around 20,000 people aged between 14 and 80 were 
asked about their dietary habits using three different survey methods (dietary history, 24h 
recall and weighing protocol) took place throughout Germany between 2005 and 2006 (61). 
The evaluations are based on the data from the two independent 24h recalls in the NVS II 
collected in a computer-assisted interview using "EPIC-SOFT" (61, 62). The data of 13,926 
people for whom both interviews were available were evaluated. Due to the presence of con-
sumption data for individual days, the 24h recall method is suitable for exposure estimates 
for both acute and chronic risk. The individual body weights of respondents were factored 
into the intake estimates. 
 
 
VELS 
The data for consumption of tea infusions by children was based on consumption data from 
the VELS study (food consumption survey to determine food intake by infants and small chil-
dren for the estimation of the acute toxicity risk from pesticide residues) (63, 64). The study 
was conducted in 2001 and 2002 and covered 816 infants and small children aged between 
6 months and less than 5 years all over Germany. The parents kept two 3-day diet logs for 
each child listing all consumed foods. Intake was calculated from the consumption data of 
the children between 2 and 5 years of age with an average body weight of 16.15 kg. Due to 
the availability of consumption data for individual days, the 2x3-day diet logs are suitable for 
exposure estimates for both acute and chronic risks, although the use of a low number of 
single-day measurements to calculate a lifelong intake is subject to uncertainties, particularly 
with regard to statements on detailed food groups or estimates with a high percentage of 
non-consumers. 
 
3.1.5.2 Data basis 
 
The content data for baby fennel tea, fennel tea, chamomile tea, herbal tea, peppermint tea, 
melissa tea and nettle tea from Table 2 were taken into account for the calculation of expo-
sure and summarised on the basis of the individual data as the group "herbal tea" (see Table 
3). 
 
Table 3: PA contents in the "herbal tea" group by LB, MB, UB1 in µg/kg of dry product 
  N Min Mean Median P95 Max 
LB 161 0.0 198.4 54.5 901.5 3428.8 
MB 161 67.8 259.9 120.6 960.7 3435.0 
Group "herbal tea" 
UB 161 133.8 330.0 190.0 1027.6 3441.2 
*Values in bold were included in the exposure assessment  
1Lower/Medium/Upper bound: see section 3.1.4 and Table 2. 
3.1.5.3 Evaluation of consumption data 
 
Adults, 14 – 80 years of age 
The food groups "tea (overall)" and "herbal tea" were taken into consideration for evaluation 
of the consumption data of the NVS II for the adult German population. Instant teas were not 
included. Long-term consumption quantities based on all respondents (including non-
consumers) and short-term maximum consumption quantities based on consumers of herbal 
tea and tea were calculated for the overall population. Separate categorisation of the herbal 
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tea varieties is not possible due to the lack of data in the NVS II. The calculated consumption 
quantity as beverage in ml was converted on the assumption that a teabag contains 2 g of 
dry product of herbal tea or tea prepared with 200 ml of hot water. It is assumed that 100% of 
the PAs migrated from the herbal tea and tea to the finished beverage. The data used for the 
exposure estimation are listed in Table 4 in consumption quantity in grams per day relative to 
body weight. The figures show that, over the long term, the adult population consumes an 
average 0.03 g of tea per kg body weight (bw), equivalent an amount of 3 ml tea infusion or 
0.15 g tea per kg body weight for the frequent consumers (95th percentile), equivalent to 
15 ml of tea infusion. If herbal tea is taken on its own, the consumed quantity decreases to 
around 0.02 g tea per kg bw (mean) or 0.09 g tea per kg bw for the frequent consumers. 
There is no breakdown of consumption by gender and age group, as these parameters are 
not included in the exposure estimation. What can be said, however, is that the consumption 
amounts for herbal tea and tea are slightly higher among women than men. Moreover, there 
are indications that people drink increasing amounts of tea with increasing age. 
Table 4: Consumption of herbal tea and tea (overall) by adults acc. to the NVS II National Food 
Consumption Study (24h recall), based on dry product 
Long-term consumption (all re-
spondents) 
Short-term 
consumption 
(consumers only)  
Share of 
consumers 
 Mean 
(g/kg bw/d) 
P 95 
(g/kg bw/d) 
P95 
(g/kg bw/d) 
Tea (overall) 43% 0.032 0.153 0.291 
Herbal tea 22% 0.015 0.093 0.269 
 
Children, 6 months to < 5 years of age 
The consumption data for long and short-term intake by children (from 6 months to under 5 
years of age and no longer being nursed) based on the 3-day diet logs from the VELS study 
were evaluated for the food group "tea (overall)" as well as the scenario "herbal tea + tea not 
specified in more detail (nns)". The evaluation is based on the conservative assumption that 
all tea varieties not specified in more detail are herbal teas. As with the adults, the calculated 
consumption quantity was converted into beverage in ml on the assumption that a teabag 
contains 2 g of dry product of herbal tea or tea prepared with 200 ml of hot water. The figures 
show that, over the long term, children consume an average 0.06 g of tea per kg body weight 
(bw) and day, equivalent to an amount of 6 ml tea infusion or 0.23 g tea per kg body weight 
and day for the frequent consumers (95th percentile), equivalent to 23 ml of tea infusion. In 
the scenario "herbal tea + tea nns", we find average daily consumption of 0.03 g tea per kg 
bw, while the frequent consumers among children consume 0.14 g tea per kg bw daily. The 
maximum consumption quantity of consumers from the diet logs was used to calculate the 
short-term consumption (acute perspective). It is seen that children in the 95th percentile 
consume a daily 0.76 g per kg bw of "tea (overall)" and 0.64 g per kg bw of "herbal tea + tea 
nns" (see Table 5). 
Table 5: Long-term and short-term consumption of herbal tea and tea (overall) by children 
(0.5 - <5 years of age) based on the VELS study 
 
Share of consumers 
 
Long-term consumption (all 
respondents) 
Short-term 
consumption 
(consumers only) 
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Mean 
(g/kg bw/d) 
P 95 
(g/kg bw/d) 
P95 
(g/kg bw/d) 
Tea (overall) 56% 0.055 0.231 0.763 
Herbal tea +  
Tea nns 
33% 0.026 0.137 0.637 
 
Detailed analysis of individual tea varieties is not possible due to the mainly low number of 
consumers. Fennel tea (with 32%) is the only herbal tea that shows a higher percentage of 
consumers and comparatively significantly higher consumption quantities. By comparison, 
chamomile and peppermint tea are represented by only 1% of consumers, and the consump-
tion quantities are lower than those for fennel tea. 
 
No significant differences can be determined based on age group. 
 
3.1.5.4 Exposure estimation 
 
For the purpose of estimating exposure to PAs via the consumption of herbal tea and tea, the 
food groups "tea (overall)" and "herbal tea" were evaluated for both adults and children using 
various consumption scenarios and taking into account the calculation approaches "lower 
bound", "medium bound" and "upper bound". The content data basis is made up of the PA 
sums of all PAs measured in the tea varieties fennel, chamomile, herbal, peppermint, 
melissa, nettle and baby fennel tea from retailers in the aforementioned special research 
project (see Table 3). 
 
Long-term intake – chronic contamination 
 
 
Table 6 and Table 7 show the long-term PA intake of adults and/or children for the following 
consumption scenarios. 
 
Scenario 1 (average consumption (mean) and average content (mean)) portrays the average 
consumer who sometimes drinks tea varieties with higher contamination levels and some-
times tea varieties with lower contents (no brand loyalty). 
Scenario 2 (high consumption (95th P.) and average content (mean)) portrays the frequent 
consumer who sometimes drinks tea varieties with higher contamination levels and some-
times tea varieties with lower contents (no brand loyalty). 
Scenario 3 (average consumption (mean) and high content (95th P.)) portrays the average 
consumer who only drinks tea varieties with higher contamination levels. 
Scenario 4 (high consumption (95th P.) and high content (95th P.)) portrays the frequent 
consumer who only drinks tea varieties with higher contamination levels. 
 
 
Adults 
 
Table 6 shows that adults in particular who belong to the group of frequent consumers can 
exhibit higher daily intakes of PAs; it should be noted that scenario 4 is based on the worst 
case situation, in which someone drinks high amounts of a tea every day and in which the 
tea in question also has high PA contents. 
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It is to be assumed that the intake for "tea (overall)" is overstated, as it includes other tea 
varieties apart from herbal tea (green and black tea, among others) that tend to have lower 
PA contents.  
 
Table 6: Long-term intake of PAs (µg/kg bw/d) via consumption of herbal tea and tea (overall) 
by adults for different calculation models and consumption scenarios 
 
  
PA intake  
(µg/kg bw/d) 
Consumption scenarios 
Calculation 
method1 
Tea 
(overall) 
Herbal 
tea 
LB 0.006 0.002 
MB 0.008 0.003 
Scenario 1: Average consumer without 
brand loyalty 
UB 0.010 0.003 
LB 0.030 0.018 
MB 0.039 0.023 
Scenario 2: Frequent consumer without 
brand loyalty 
UB 0.050 0.030 
LB 0.027 0.009 
MB 0.029 0.010 
Scenario 3: Average consumer with 
brand loyalty to highly contaminated 
herbal teas UB 0.031 0.010 
LB 0.135 0.081 
MB 0.144 0.086 
Scenario 4: Frequent consumer with 
brand loyalty to highly contaminated 
herbal teas (worst case) UB 0.154 0.092 
1Lower/Medium/Upper bound: see section 3.1.4 and Table 2. 
 
The exposure estimation was based on the consumption data for the adult population without 
taking account of age and gender differences. It can be assumed, however, that men and the 
younger age groups ingest slightly lower quantities of PAs through the consumption of herbal 
tea and tea than the overall population. 
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Children (0.5 months - <5 years of age) 
 
Table 7: Long-term intake of PAs (µg/kg bw/d) via consumption of herbal tea and tea (overall) 
by children (0.5 months - <5 years of age) for different calculation models and consumption 
scenarios 
  
PA intake 
(µg/kg bw/d) 
Consumption scenarios 
Calculation  
method1 
Tea 
(overall) 
Herbal tea +  
tea nns 
LB 0.011 0.005 
MB 0.014 0.007 
Scenario 1: Average consumer without 
brand loyalty 
UB 0.018 0.009 
LB 0.046 0.027 
MB 0.060 0.036 
Scenario 2: Frequent consumer without 
brand loyalty 
UB 0.076 0.045 
LB 0.050 0.023 
MB 0.053 0.025 
Scenario 3: Average consumer with 
brand loyalty to highly contaminated 
herbal teas UB 0.057 0.027 
LB 0.208 0.124 
MB 0.222 0.132 
Scenario 4: Frequent consumer with 
brand loyalty to highly contaminated 
herbal teas (worst case) UB 0.237 0.141 
1Lower/Medium/Upper bound: see section 3.1.4 and Table 2. 
 
 
Children (0.5 months - <5 years of age) sometimes also have not inconsiderable intake 
quantities of PAs due to the long-term consumption of herbal tea and tea (overall). Due to the 
higher consumption quantities relative to body weight, the PA intake of children is higher than 
that of adults. It must be taken into account, however, that (in contrast to the situation with 
adults) the food group "herbal tea" in this case also includes quantities of tea whose variety 
was not exactly listed in the diet logs. The conservative assumption was made that all these 
teas are herbal teas. 
 
Short-term intake – acute contamination 
 
Table 8 shows the short-term PA intakes of adults and children for two consumption scenar-
ios. In the first scenario, the data are based on the consumption of herbal tea and tea (over-
all) with average PA contents. This means that there is no preference for a specific tea vari-
ety (without brand loyalty (without brand loyalty). In the second scenario, it is assumed that 
the consumed herbal tea and tea (overall) has high contents; in other words, that there is a 
preference for certain tea varieties (with brand loyalty). 
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Table 8: Short-term intake of PAs (µg/kg bw/d) via consumption of herbal tea and tea by adults 
and children for different calculation models and consumption scenarios 
PA intake (µg/kg bw/d) 
  
Adults Children 
Consumption 
scenarios 
Calculation  
method1 
Tea (over-
all) Herbal tea 
Tea (over-
all) 
Herbal tea 
+ tea nns 
LB 0.060 0.060 0.151 0.126 
MB 0.078 0.078 0.198 0.166 
Without brand loy-
alty: 95.P. consump-
tion*      Mean con-
tent 
UB 0.099 0.099 0.252 0.210 
LB 0.270 0.270 0.688 0.574 
MB 0.288 0.288 0.733 0.612 
With brand loyalty: 
95.P. consumption* 
95.P. content 
(worst case) UB 0.308 0.308 0.784 0.655 
1Lower/Medium/Upper bound: see section 3.1.4 and Table 2. 
 
As with long-term intake, children show a far higher burden than the adult population when to 
comes to short-term PA intake (see Table 8). Moreover, the intake quantities with assumed 
brand loyalty are 3 to 5 times higher than in the scenario without brand loyalty. 
 
One-time consumption of a herbal tea infusion with high contamination levels is certainly a 
realistic proposition. Based on the available data, however, it is difficult to make any state-
ment on the probability of longer-term consumption of highly contaminated herbal tea and tea 
(overall), as the content data sometimes varies widely even within the same tea variety (see 
Table 2). It can therefore be assumed that the consumed herbal tea and tea (overall) also 
has differing PA contents and therefore also leads to differing intake amounts among con-
sumers with brand loyalty. 
 
What remains to be taken into account is that the content data for the individual PAs shows a 
high number of values below the limit of detection and the limit of quantification, and this is 
why the PA sums are mainly determined by the various limits of detection and limits of quan-
tification of the 17 PAs. The actual exposure of the consumer is basically in between the LB 
and UB calculation approaches, with LB being an underestimation and UB an overestima-
tion. 
Due to the low number of cases supplying the content data and given the low number of 
consumers, it is not possible to provide any detailed overview of PA intake through individual 
tea varieties. Consequently, the exposure estimation was only possible on the level of an 
overall perspective of herbal tea or tea (overall), and this is associated with uncertainties that 
result in overestimation of intake levels. 
 
3.1.6 Risk characterisation 
In general, statements on the necessity to limit PA intake through food are primarily directed 
towards avoiding the risk of cancer and were based on estimations of chronic consumption of 
the foods in question. In addition, it is also necessary to assess potential risks of acute toxic-
ity, e.g. in cases of possible high short-term exposures. 
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With regard to the question of whether PAs have a carcinogenic effect in humans, there are 
no robust epidemiological studies or follow up surveys for cases of poisoning over longer 
periods of time. Based on the entirety of experimental findings on metabolism, activation 
mechanism, DNA adduct formation, genotoxicity and carcinogenicity, it should be considered 
that PAs can also have a carcinogenic effect in humans. 
 
At a BfR expert meeting on 4 March 2010, however, basic agreement was reached to give 
preference to the MOE approach for the risk assessment of substances with genotoxic and 
carcinogenic properties over the previous practice based on the assessment approach used 
in the field of medicinal products(2). The corresponding assessment proposed by COT in the 
UK in 2008, in which PAs are considered as a group with cumulative effect with regard to 
their carcinogenic effect was seen as being suitable. In this approach, the derived BMDL10 
(Benchmark Dose Lower Confidence Limit, 10%) for lasiocarpine of 0.073 mg/kg bw/day is 
used as the basis for the MOE estimation. The precondition for this assessment is that a car-
cinogenic potency equivalent to that of lasiocarpine is assumed for all detectable PAs. This 
"cumulative assessment group approach" might, however, overstate the actual risk. In view 
of the lack of data, comparative statements on the carcinogenic effect of individual PAs are 
currently not possible. For substances with genotoxic and carcinogenic effects, it is currently 
accepted within the EU that the exposure levels can be regarded as being of low concern if 
the MOE is 10000 or above (2). This means that daily doses of 0.007 µg PA/kg bw are 
viewed as posing little risk in terms of carcinogenic effects. The BfR therefore recommends 
that the PA intake from all sources should not constitute an MOE of less than 10000. How-
ever, total exposure to PAs from all food sources should generally be kept as low as possi-
ble. 
 
3.1.6.1 Long-term intake of PAs via teas including herbal teas 
 
Adults 
Table 9 shows that, among adults, the MOE values are only above 10000 for average con-
sumers of herbal tea and tea (overall) (LB) who do not prefer a certain variety. All other cal-
culation approaches result in MOE values below 10000 for the adult population and in par-
ticular for frequent consumers with brand loyalty. It is to be assumed, however, that the in-
take figures for herbal tea and tea (overall) are on the high side, as they include consumption 
amounts of other tea varieties apart from herbal tea that tend to have lower PA contents. 
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Table 9: Long-term intake of PAs (µg/kg bw/d) via consumption of herbal tea and tea by adults 
for different calculation models and consumption scenarios 
  
PA intake 
(µg/kg bw/d) 
MOE (based on a BMDL10 of 
0.073 mg PA/kg bw/day) 
Consumption scenarios Calculation 
method1 
Tea 
(overall) 
Herbal- 
tea 
Tea 
(overall) 
Herbal- 
tea 
LB 0.006 0.002 12268 36803 
MB 0.008 0.003 9362 28085 
Scenario 1: Average con-
sumer without brand loy-
alty UB 0.010 0.003 7373 22118 
LB 0.030 0.018 2454 4089 
MB 0.039 0.023 1872 3121 
Scenario 2: Frequent con-
sumer without brand loy-
alty UB 0.050 0.030 1475 2458 
LB 0.027 0.009 2699 8098 
MB 0.029 0.010 2533 7599 
Scenario 3: Average con-
sumer with brand loyalty to 
highly contaminated herbal 
teas UB 0.031 0.010 2368 7104 
LB 0.135 0.081 540 900 
MB 0.144 0.086 507 844 
Scenario 4: Frequent con-
sumer with brand loyalty to 
highly contaminated herbal 
teas (worst case) UB 0.154 0.092 474 789 
1Lower/Medium/Upper bound: see section 3.1.4 and Table 2. 
 
Children (0.5 months - <5 years of age) 
Table 10: Long-term intake of PAs (µg/kg bw/d) via consumption of herbal tea and tea by chil-
dren (0.5 months - <5 years of age) for different calculation models and consumption scenarios 
  
PA intake 
(µg/kg bw/d) 
MOE (based on a BMDL10 of 
0.073 mg PA/kg bw/day) 
Consumption scenarios Calculation 
method1 
Tea 
(overall) 
Herbal tea 
+  tea nns 
Tea 
(overall) 
Herbal 
tea 
LB 0.011 0.005 6691 14155 
MB 0.014 0.007 5106 10802 
Scenario 1: Average con-
sumer without brand loyalty 
UB 0.018 0.009 4021 8507 
LB 0.046 0.027 1593 2686 
MB 0.060 0.036 1216 2050 
Scenario 2: Frequent con-
sumer without brand loyalty 
UB 0.076 0.045 957 1614 
LB 0.050 0.023 1472 3114 
MB 0.053 0.025 1382 2923 
Scenario 3: Average con-
sumer with brand loyalty to 
highly contaminated herbal 
teas UB 0.057 0.027 1292 2732 
LB 0.208 0.124 351 591 
MB 0.222 0.132 329 555 
Scenario 4: Frequent con-
sumer with brand loyalty to 
highly contaminated herbal 
teas (worst case) UB 0.237 0.141 308 519 
1Lower/Medium/Upper bound: see section 3.1.4 and Table 2. 
 
With children as well (0.5 months - <5 years), MOE values above 10000 are only calculated 
for average consumers of herbal tea (LB, MB) who do not favour a specific variety. Due to 
the higher consumption amounts relative to body weight, the PA intake of children is higher 
than that of adults in the various scenarios. It must be taken into account, however, that (in 
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contrast to the situation with adults) the food group "herbal tea" in this case also includes 
quantities of tea whose variety was not exactly listed in the diet logs. The conservative as-
sumption was made that all these teas are herbal teas. 
 
Overall, therefore, the MOE values in scenario 4 (worst case), in which frequent consumers 
exclusively consume herbal teas/teas with higher levels of contamination, are considerably 
below 10000 for both children and adults. It is to be assumed that the intake for "tea (over-
all)" is overstated, as it includes other consumption amounts of other tea varieties apart from 
herbal tea (green and black tea, among others) that tend to have lower PA contents. The 
MOE values for herbal tea infusions are in a range from 900-789 (LB-UB) for adults (Table 9) 
and a range of 591-519 (LB-UB) for children (Table 10). 
 
With regard to the induction of non-neoplastic damage, a value of 0.1 µg PA (riddelliine)/kg 
bw/day was derived at which no non-neoplastic damage is yet expected (39, 53). Levels are 
above this value for children and adults based on the assumptions of scenario 4.  
 
At the same time, however, this exposure scenario where a person drinks a high amount of 
highly contaminated tea/herbal tea on a daily basis over a long period of time is highly im-
probable in practice. 
 
3.1.6.2 Short-term intake of PAs in teas including herbal teas 
 
As with long-term intake, children show a far higher PA exposure per kg body weight than 
the adult population whith regard to short-term PA ingestion (see Table 8). One-time con-
sumption of a herbal tea infusion with high contamination levels is certainly a realistic propo-
sition. 
 
A comparison with the poisoning cases in children outlined in 3.2.1.3.1 (40-42) provides a 
posibility for dose-related risk estimation. The estimated intake of an alkaloid mixture with 
riddelliine and retrorsine-N-oxide as the main components led to death in a 2 month-old boy 
in doses of 3 mg/kg bw/day (= 3000 µg/kg bw/day) over a period of 4 days, while doses of 
0.8-1.7 mg/kg bw/day (= 800-1700 µg/kg bw/day) over a period of 14 days resulted in ascites 
and pleural effusion in a 6 month-old girl, followed by a liver fibrosis 2 months later, which 
finally developed a liver cirrhosis after 6 months. 
 
The intake for "tea (overall)" might result in an overestimation of exposure, as it includes 
other tea varieties apart from herbal tea (green and black tea, among others) that tend to 
have lower PA contents. The "worst case" is therefore assumed to be high consumption of 
herbal tea with high PA content, where a child would consume 0.655 µg PA/kg bw/day via a 
herbal tea infusion (Table 8). This supplies a differential of factor 4580 plus for the boy rela-
tive to the lethal dose and a differential of between 1221 and 2595 for the girl relative to the 
dose that caused liver cirrhosis. Therefore, acute damage to health from short-term intake 
(e.g. over a period of 14 days) of PAs in herbal tea/tea infusions in doses corresponding to 
the scenarios outlined in Table 7 is considered to be improbable. 
 
In general, various uncertainties have to be taken into account when estimating PA intake. 
First, there was no differentiation between the consumption of different tea varieties, for ex-
ample, and this can lead to overestimation or underestimation of the consumption of individ-
ual tea varieties. It can be assumed, however, there are no major differences in the amounts 
of tea consumed, particularly in the case of frequent consumers. It is also not known whether 
the measured contents reflect the actual distribution of PAs in herbal teas on the German 
market. 
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The content of 1,2-unsaturated pyrrolizidine alkaloids measured in the herbal tea and tea 
samples from different batches vary considerably in both qualitative and quantitative terms. 
One possible reason is that the plants used to make the herbal teas grew together with vari-
ous wild herbs containing PAs and that components from the latter contaminated the herbal 
teas. This appears plausible, as in the past specific salade has been contaminated with plant 
components containing PAs, namely blossoms and leaves of the common groundsel (Se-
necio vulgaris L.). The BfR published a corresponding risk assessment in 2007 (11). The 
increasing spread of Senecio species containing PAs in moderate climate zones was already 
known (5, 11), and back then the BfR recommended that horticultural and agricultural prod-
ucts be checked for contamination with corresponding plants. At the time, there were good 
reasons to focus these efforts on lettuce and leaf vegetables as well as herbs, and it was 
pointed out that it appeared necessary to train harvesting personnel accordingly. It must be 
taken into account that other wild herbs unrelated to Senecio species containing PAs may 
contaminate plant material used for food production. 
 
3.2 Conclusions, framework for action and measures 
 
Based on the entirety of experimental findings on metabolism, activation mechanism, DNA 
adduct formation, genotoxicity and carcinogenicity, it should be considered that PAs can also 
have a carcinogenic effect in humans. However, the incomplete data basis does not permit 
any robust statements on the differences between the individual PAs in terms of their car-
cinogenic potential and their toxicity. 
 
The use of equivalence factors based on the ratio of the LD 50 values measured for i.p. ad-
ministration of the individual PAs to rats is not considered suitable for assessment of the 
longer-term exposure to PAs and the resulting risks (in particular carcinogenic effects), as 
they do not take into account possible differences between individual PAs in terms of toxi-
cokinetics following oral administration and in terms of toxicodynamics following longer-term 
exposure. The BfR therefore regards PAs as a group of substances with cumulative effect 
with respect to their carcinogenic effect. It is possible, however, that this "cumulative as-
sessment group approach" overestimates the risk. Using the MOE approach for the risk as-
sessment of substances with genotoxic and carcinogenic properties, an approach which is 
currently standard in the EU (2), the derived BMDL10 (Benchmark Dose Lower Confidence 
Limit, 10%) for lasiocarpine of 0.073 mg/kg bw/day is used as the basis for the MOE estima-
tion. It is assumed that the exposure levels can be seen as being of low concern if the MOE 
is 10000 or above (2). The BfR therefore recommends that considering the PA intake from all 
sources, an MOE should not fall below 10000. However, total exposure to PAs from all foods 
should generally be kept as low as possible. 
 
In view of the genotoxic and carcinogenic effects of PAs, efforts should be made to minimise 
the PA contents in herbal teas and teas in order to minimise the putative higher cancer risk of 
frequent consumers and in particular of children, whose higher sensitivity to PA-related ef-
fects must be taken into account. This measure is also deemed necessary, because possible 
additional exposure to PAs may occur from other food sources like honey. 
 
Although unexpectedly high PA contents were measured in individual herbal tea and tea 
samples, an acute health risk is regarded as improbable, even if tea was brewed up with high 
doses. 
 
Based on the available data, the BfR concludes that the adults and children who belong to 
the frequent consumers of herbal tea infusions are possibly at increased risk of impaired 
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health due to cancer, particularly if they consume products with high PA content over longer 
periods of time. 
 
It is considered to be a matter of urgency that the economic operators investigate the causes 
of the contamination. This includes botanical analysis of the plant material to which the oc-
currence of the PAs found in the herbal tea and tea samples is attributed. The companies in 
question should evaluate ways to reduce PA content by improving cultivation, harvesting and 
cleaning methods. 
 
In order to avoid the marketing of contaminated batches and to protect the consumer, it is 
recommended that herbal tea batches should be checked for PA content prior to marketing. 
 
The BfR also recommends that the food control authorities should analyze the PA content of 
herbal tea and tea samples. The Institute also recommends the gathering of representative 
data on PAs in herbal tea and tea samples as part of the food monitoring programme. 
 
The measured data for PA content for the non-representative tea varieties rooibos tea, green 
tea and black tea is based on only small samples and should be followed up; if necessary, 
the corresponding measures must be extended to include these tea varieties as well.  
 
The BfR recommends that the Federal Institute for Drugs and Medical Devices should be 
informed, since the findings may also be of relevance for medicinal teas. 
 
This assessment is based on the data currently available to the BfR. The risk assessment is 
to be considered preliminary due to the non-representative data sample and the significant 
gaps in knowledge. 
 
Due to the existing uncertainties discussed, the BfR is currently not able to deduce or even 
specify a limit value for PAs in herbal tea/tea. The available knowledge on the causes of PA 
contamination is insufficient, and data on actual consumption of the individual varieties is 
incomplete. It has not yet been possible to adequately determine any variation between dif-
ferent batches of a product. 
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